spacer
home > ict > autumn 2009 > unify and consolidate
PUBLICATIONS
International Clinical Trials

Unify and Consolidate

 

Pharmaceutical companies face growing competition and tremendous pressure to improve margins while also responding to increasing challenges driven by the evolution toward personalised medicine, with growing demand for treatments targeted at smaller populations with very specific disease states. Consequently, a paradigm shift is underway in the way in which clinical trials are conducted. Pharmaceutical companies are pursuing new ways to reduce clinical development costs, including conducting clinical trials in lower cost areas, such as emerging countries. While the globalisation of clinical trials across a diverse range of patient populations provides research scientists with greater access to subjects and lower recruitment and operational costs, these trials involve much greater complexity, often straining the capabilities of the laboratory informatics systems employed.

Traditionally, diagnostic clinical patient testing is managed using a laboratory information system (LIS). To address the complex demands of clinical trial specimen management and laboratory testing, some organisations find that they need a number of informatics systems alongside a LIS, including laboratory information management systems (LIMS), biorepositories, electronic laboratory notebooks (ELN) and scientific data management systems (SDMS). Of course, relying on a number of discrete systems can cause inefficiencies in the process of data archiving, data searches and information sharing.

A unified laboratory informatics platform seeks to overcome these inefficiencies by integrating LIS and LIMS, including clinical trial management and biorepository management capabilities, along with SDMS and ELN capabilities.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Joe Tehan is Senior Account Manager, Clinical Operations, for the STARLIMS Corporation. With over nine years’ experience with Mediware Information Systems, and over nine years’ experience in the laboratory group of McKesson Provider Technologies, Joe’s knowledge of and experience in the hospital and clinical reference laboratory marketplace is extensive. Joe holds a BSc in Computer Science from the Washington University School of Engineering in St Louis, US.
spacer
Joe Tehan
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Clinerion adds Patient Network Explorer Coverage to three new Hospitals in Brazil

Basel, Switzerland, April 19th, 2022: Clinerion has extended its patient coverage in Brazil to three new hospitals with the help of partner iHealth Group. This raises the footprint of Clinerion’s Patient Network Explorer to 22 healthcare organisations and over 8 million patients in Brazil.
More info >>

White Papers

Backward Thinking: The Reverse Engineering of A Pressurized Metered Dose Inhaler

Development of a generic equivalent to a current marketed pressurized metered dose inhaler (pMDI) product brings immense challenges. Thorough analysis is critical to gain a comprehensive understanding of the physical attributes and pharmaceutical performance of the reference marketed product. Many factors need to be assessed, understood and combined in order to successfully develop a generic pMDI which will meet the regulatory and quality requirements as an equivalent product in the anticipated target market. Significant information about the reference marketed product can be obtained from a thorough review of published literature, specifically the Summary of Product Characteristics (SPC) and Patient Information Leaflet (PIL). Additionally, baselining the reference marketed product for pharmaceutical performance offers a working target specification for in-vitro correlation. It will ensure the smoothest possible path to commercialization and maximize return on investment. In addition, baselining of the reference marketed product is done to understand batch-to-batch variability and product performance over the stated shelf life to establish targets for critical quality attributes (CQAs), which can be applied to the generic equivalent pMDI.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement